EA201070237A1 - Четвертичные опиоидные карбоксамиды - Google Patents

Четвертичные опиоидные карбоксамиды

Info

Publication number
EA201070237A1
EA201070237A1 EA201070237A EA201070237A EA201070237A1 EA 201070237 A1 EA201070237 A1 EA 201070237A1 EA 201070237 A EA201070237 A EA 201070237A EA 201070237 A EA201070237 A EA 201070237A EA 201070237 A1 EA201070237 A1 EA 201070237A1
Authority
EA
Eurasian Patent Office
Prior art keywords
quarterly
carboxamides
opioid
compounds
reduce
Prior art date
Application number
EA201070237A
Other languages
English (en)
Other versions
EA020658B1 (ru
Inventor
Марк П. Уэнтлэнд
Original Assignee
Ренссилэйер Политекник Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ренссилэйер Политекник Инститьют filed Critical Ренссилэйер Политекник Инститьют
Publication of EA201070237A1 publication Critical patent/EA201070237A1/ru
Publication of EA020658B1 publication Critical patent/EA020658B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Описаны соединенияСоединения можно использовать для ослабления побочного действия терапевтических опиатов.
EA201070237A 2007-08-09 2008-08-08 Четвертичные опиоидные карбоксамиды EA020658B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95496007P 2007-08-09 2007-08-09
PCT/US2008/072632 WO2009023567A1 (en) 2007-08-09 2008-08-08 Quaternary opioid carboxamides

Publications (2)

Publication Number Publication Date
EA201070237A1 true EA201070237A1 (ru) 2010-10-29
EA020658B1 EA020658B1 (ru) 2014-12-30

Family

ID=39941437

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070237A EA020658B1 (ru) 2007-08-09 2008-08-08 Четвертичные опиоидные карбоксамиды

Country Status (15)

Country Link
US (4) US8263807B2 (ru)
EP (1) EP2190819B1 (ru)
JP (1) JP5581211B2 (ru)
KR (1) KR101519682B1 (ru)
CN (1) CN101827819B (ru)
AU (1) AU2008286979B2 (ru)
BR (1) BRPI0815020A2 (ru)
CA (1) CA2694497C (ru)
EA (1) EA020658B1 (ru)
ES (1) ES2586245T3 (ru)
HK (1) HK1141295A1 (ru)
IL (1) IL203459A (ru)
MX (1) MX2010001371A (ru)
NO (1) NO341089B1 (ru)
WO (1) WO2009023567A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101274107B1 (ko) 2007-11-30 2013-06-13 퍼듀 퍼머 엘피 벤조모르판 화합물
CA2754984C (en) * 2009-03-19 2018-06-26 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
NZ600379A (en) 2009-12-04 2014-05-30 Alkermes Pharma Ireland Ltd Morphinan derivatives for the treatment of drug overdose
US8436175B2 (en) 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
WO2012005795A1 (en) * 2010-07-08 2012-01-12 Alkermes, Inc. Process for the synthesis of substituted morphinans
EP2407469A1 (en) * 2010-07-13 2012-01-18 Chemo Ibérica, S.A. Salt of sitagliptin
SI2608670T1 (sl) 2010-08-23 2019-04-30 Alkermes Pharma Ireland Limited Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil
JP2014505113A (ja) * 2011-02-14 2014-02-27 アルカーメス，インコーポレイテッド 末梢作用性μオピオイドアンタゴニスト
SG192973A1 (en) * 2011-03-03 2013-09-30 Cadila Healthcare Ltd Novel salts of dpp-iv inhibitor
WO2012138888A1 (en) * 2011-04-05 2012-10-11 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
AU2012275181B2 (en) * 2011-06-29 2016-04-07 Alkermes, Inc. Peripherally acting opioid compounds
EP2788358B1 (en) * 2011-12-08 2018-08-29 Purdue Pharma LP Quaternized buprenorphine analogs
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP3415148A1 (en) 2011-12-15 2018-12-19 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
US20140066475A1 (en) 2012-09-04 2014-03-06 Euro-Celtique S.A. Method For Treating Pruritus
AU2014268361B2 (en) 2013-05-24 2018-09-06 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
US20160243112A1 (en) * 2015-02-25 2016-08-25 Alkermes, Inc. Treatments for alzheimer's related diseases and disorders
CN113248435B (zh) * 2020-02-13 2024-06-04 上海翰森生物医药科技有限公司 3-甲酰胺基-4-羟基纳曲酮氘代衍生物、其制备方法及其在医药上的应用
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES252980A1 (es) 1958-10-30 1960-11-01 Boehringer Sohn Ingelheim Procedimiento para la obtencion de nuevas sales cuaternarias, terapéuticamente valiosas, de la normorfina y de sus derivados
DE2254298A1 (de) * 1972-11-06 1974-05-16 Boehringer Sohn Ingelheim Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US4032529A (en) * 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
GB1511319A (en) * 1974-09-20 1978-05-17 Sterling Drug Inc 2,6-methane-3-benzazocine derivatives and their preparation
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
FR2514644A1 (fr) * 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
CA1315689C (en) * 1987-09-03 1993-04-06 Leon I. Goldberg Quarternary derivatives of noroxymorphone which relieve nausea and emesis
PL327943A1 (en) * 1996-01-10 1999-01-04 Smithkline Beecham Spa Condensed heterocyclic derivatives of morphonoide (ii)
ES2121553B1 (es) 1996-12-23 1999-06-16 Univ Santiago Compostela Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion.
WO2001014382A1 (fr) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesiques contenant des derives sel d'ammonium quaternaire comme principe actif
EP1206264A2 (en) * 1999-08-25 2002-05-22 Barrett R. Cooper Compositions and methods for treating opiate intolerance
IL149600A0 (en) * 1999-11-29 2002-11-10 Adolor Corp Novel methods and compositions involving opioids and antagonists thereof
AU2002227135B2 (en) * 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
EP1543010B1 (en) * 2002-09-25 2007-04-25 Euro-Celtique S.A. N-substituted hydromorphones and the use thereof
ATE444295T1 (de) * 2002-11-08 2009-10-15 Mallinckrodt Inc Verfahren zur herstellung von quaternäre n-alkyl morphinan alkaloid salzen
AU2005304950B2 (en) 2004-11-05 2010-12-09 Rensselaer Polytechnic Institute 4-Hydroxybenzomorphans
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
WO2007014137A2 (en) 2005-07-21 2007-02-01 Rensselaer Polytechnic Institute 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
US8163701B2 (en) * 2005-08-19 2012-04-24 Signature Therapeutics, Inc. Prodrugs of active agents

Also Published As

Publication number Publication date
BRPI0815020A2 (pt) 2015-03-10
CN101827819B (zh) 2013-06-12
ES2586245T3 (es) 2016-10-13
HK1141295A1 (zh) 2010-11-05
AU2008286979A1 (en) 2009-02-19
EA020658B1 (ru) 2014-12-30
US8563572B2 (en) 2013-10-22
KR101519682B1 (ko) 2015-05-19
JP2010535814A (ja) 2010-11-25
NO341089B1 (no) 2017-08-21
US20090197905A1 (en) 2009-08-06
US20120302594A1 (en) 2012-11-29
US8263807B2 (en) 2012-09-11
US20170095469A1 (en) 2017-04-06
EP2190819A1 (en) 2010-06-02
CA2694497A1 (en) 2009-02-19
WO2009023567A1 (en) 2009-02-19
IL203459A (en) 2016-02-29
KR20100053627A (ko) 2010-05-20
MX2010001371A (es) 2010-03-10
EP2190819B1 (en) 2016-05-25
CA2694497C (en) 2016-07-12
AU2008286979B2 (en) 2013-03-28
NO20100289L (no) 2010-03-02
JP5581211B2 (ja) 2014-08-27
US20140107143A1 (en) 2014-04-17
CN101827819A (zh) 2010-09-08

Similar Documents

Publication Publication Date Title
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
CY2017042I2 (el) Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk
CY2017010I1 (el) Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
CY2014006I1 (el) Μεθοδοι θεραπευτικης αγωγης χρησιμοποιωντας γλυκοπεγκυλιωμενο g-csf
BRPI0916931A2 (pt) agentes terapêuticos
EA201270254A1 (ru) Производные 5-фторпиримидинона
DK3248978T3 (da) Deutererede morphinanforbindelser
EA201100037A1 (ru) Органические соединения
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
WO2007115821A3 (en) Organic compounds
IL207955A (en) Small molecules contain boron as anti-inflammatory substances
NO20090079L (no) Arylsulfonamider med analgesisk virkning
ATE459622T1 (de) Tropanverbindungen
DK2144905T3 (da) Terapeutiske midler
EP2225671A4 (en) USE OF REPUTATIONAL MEASURES TO IMPROVE THE SEARCH REVIEW
DK2420223T3 (da) Vandige farmaceutiske sammensætninger med borat-polyol-komplekser
DK3300729T3 (da) Terapeutiske sammensætninger indeholdende macitentan
DK3211005T3 (da) Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
SMT201600041B (it) Agenti terapeutici 713
BRPI0818598A2 (pt) agentes terapêuticos - 802
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
BRPI0909764A2 (pt) compostos terapêuticos
BRPI0906879A2 (pt) Compostos terapêuticos

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM RU